Prospective Cohort Study of Neurogenetic Diseases (CNGD)

University Hospital of Bordeaux

Status: Enrolling

Conditions: Genetic Disease; Nervous System Diseases

Treatments: Procedure: Control cohort; Procedure: Patient cohort

Study type: Interventional

Funder types: Other

Identifiers

NCT06048523

CHUBX 2022/73

Details and patient eligibility

About

Neurogenetic diseases (NGD) represent rare and hereditary forms of neurological diseases. The goal of CNGD is to create a one-window approach for NGDs, to facilitate and accelerate participation in research projects through deep phenotyping and the availability of low-cost biological samples for research teams. It is positioned as a true hub allowing new connections between clinical and basic research teams and ultimately as an incubator for translational projects for NGDs, in order to be able to initiate therapeutic trials, the ultimate objective of clinical and translational research.

Full description

Neurogenetic diseases (NGDs) represent rare inherited forms of neurological diseases. They constitute a constellation of different diseases, affecting neurodevelopment (syndromic or non-syndromic intellectual disabilities (ID), with or without autism spectrum disorders (ASD), epileptic encephalopathies, neurodevelopmental disorders (NDD) with or without ID... ) or leading to early neurodegeneration (Huntington's and Huntington-like disease, hereditary ataxias, hereditary spastic paraplegias (HSP), primary dystonias, neurodegeneration due to intracerebral iron accumulation (NBIA), neurometabolic diseases, etc.). Progress in the knowledge of the genetic causes of NGDs is unceasing, with the discovery of new genes involved in their determinism being continuous. As a result, the boundary between routine care and clinical research is extremely narrow and blurred, and the two activities are totally intertwined and interdependent in the care of patients.

For patients with NGDs already characterized by molecular genetics, at an early, intermediate or presymptomatic stage, we will perform a comprehensive annual standardized clinical and paraclinical evaluation for deep phenotyping as part of routine care; collection of biological samples (annual blood and urine sampling, optional skin biopsy and optional cerebrospinal fluid (CSF) sampling), for functional analyses and better understanding of the pathophysiological mechanisms involved. This study will last 3 years

Enrollment: 150 estimated patients

Sex: All

Ages: 6+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patient-specific inclusion criteria

• Age ≥ 6 years

• Patient with a molecularly identified NGD

  o Specific inclusion criteria for controls

• For the 10 controls with lumbar puncture (LP): person who performed an LP for medical reasons and who consented to participate in the collection of biological samples

• Age ≥ 18 years

• Person matched in age (+/- 5 years) and sex to adult patient with NGD at the time of collection

Exclusion criteria

• Participation in an interventional clinical trial that may interfere with our study
• Refusal of blood collection
• Pregnant and breastfeeding women
• Only for patients performing LP: Contraindication to LP
• Specific non-inclusion criteria for controls: Criterion of a neurodegenerative or inflammatory pathology of the central nervous system

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

150 participants in 2 patient groups

Patient cohort

Other group

Description:

Patients with a molecularly identified NGD (80 patients in total of which 15 with LP (Lumbar Puncture) and of which 30 with cutaneous biopsy)

Treatment:

Procedure: Patient cohort

Control cohort

Other group

Description:

Patients control: 10 controls with lumbar puncture and 10 controls without LP (Lumbar Puncture)

Treatment:

Procedure: Control cohort